68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer. (September 2016)

• Record Type: Journal Article
• Authors: Ahmadzadehfar, Hojjat; Schlenkhoff, Carl Diedrich; Rogenhofer, Sebastian; Yordanova, Anna; Essler, Markus
• Is Part Of: Clinical nuclear medicine. Volume 41:Number 9(2016)
• Publication Date: 2016-09
• Subjects: Ga-PSMA -- 223Ra -- prostate cancer -- bone metastases -- radionuclide therapy; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000001286
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: A 64-year-old man with prostate cancer and an increasing prostate-specific antigen (PSA) level under therapy with abiraterone acetate underwent a therapy with 223 Ra. Before the first therapy and 4 weeks after the last cycle, the patient underwent 68 Ga-PSMA PET, which showed a clear response of bone metastases.